{"title":"[Benefit of treatment with rituximab in autoimmune myasthenia gravis in children].","authors":"Agathe Molimard, Cyril Gitiaux, Christine Barnerias, Frédérique Audic, Arnaud Isapof, Ulrike Walther-Louvier, Claude Cances, Caroline Espil-Taris, Davion Jean-Baptiste, Susana Quijano-Roy, Coraline Grisel, Brigitte Chabrol, Isabelle Desguerre","doi":"10.1051/medsci/2024132","DOIUrl":null,"url":null,"abstract":"<p><p>The therapeutic management of autoimmune myasthenia gravis in children presents several particularities, which motivate the optimization of therapeutic management. On the one hand, corticosteroids are recommended as first-line immunosuppressive therapy, despite their significant adverse effects on growth, behavior, bone development, etc. On the other hand, in the absence of clinical trials in children, the place of promising new immunosuppressive therapies remains ill-defined. Rituximab is the non-steroidal immunosuppressant most widely used in France for autoimmune myasthenia gravis in children. Its use, without standardization of practices or monitoring of efficacy and safety, remains non-consensual. The aim of this study is to propose a new role for rituximab in the management of autoimmune myasthenia in children.</p>","PeriodicalId":18205,"journal":{"name":"M S-medecine Sciences","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"M S-medecine Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1051/medsci/2024132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The therapeutic management of autoimmune myasthenia gravis in children presents several particularities, which motivate the optimization of therapeutic management. On the one hand, corticosteroids are recommended as first-line immunosuppressive therapy, despite their significant adverse effects on growth, behavior, bone development, etc. On the other hand, in the absence of clinical trials in children, the place of promising new immunosuppressive therapies remains ill-defined. Rituximab is the non-steroidal immunosuppressant most widely used in France for autoimmune myasthenia gravis in children. Its use, without standardization of practices or monitoring of efficacy and safety, remains non-consensual. The aim of this study is to propose a new role for rituximab in the management of autoimmune myasthenia in children.
期刊介绍：
m/s offers high-quality review articles in French, covering all areas of biomedical and health research, in a monthly magazine format (10 issues / year). m/s is read by the whole French-speaking community, in France but also in Belgium, Switzerland, Canada, Morocco, Algeria, Tunisia etc. m/s is not a primary publication, and thus will not consider unpublished data. Most articles are invited by the Editors, but spontaneous proposals are welcomed. Each issue combines news and views on the most recent scientific publications, as well as broadly accessible and updated review articles on a specific topic, and essays on science and society, history of science, public health, or reactions to published articles. Each year, m/s also publishes one or two thematic issues focused on a research topic of high interest. All review articles and essays are peer-reviewed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
